March 3
2016

INCA – First Executive Director, Teodora Kolarova

PRESS RELEASE, 

March 2, 2016

 

The International Neuroendocrine Cancer Alliance (INCA)
Appoints First Executive Director, Teodora Kolarova

inca Teo

Ron Hollander, President of the International Neuroendocrine Cancer Alliance (INCA) and Executive Director of the NET Research Foundation (USA), is pleased to announce the appointment of Teodora Kolarova of Bulgaria as INCA’s first Executive Director. Ms. Kolarova was INCA’s President in 2014-2015 and will serve as Executive Director under a contract with her public relations and strategic consultancy company PR Net, based in Sofia, Bulgaria.

Read more at http://incalliance.org/inca-appoints-first-executive-director/

November 6
2015

World NET Cancer Day November 10

November 10 is World NET Awareness Day and we need your help!
Use your social media accounts to help us spread the news about NET Cancers. Using the power of social media we are hoping to highlight key messages on the plight of NET Cancer patients.

Share the messages with your friends and followers

Key messages: 
• 5-7 out of every 100.000 are diagnosed with #netcancer each year http://incalliance.org

• 50% of #netcancer patients have secondary growths at diagnosis http://incalliance.org

• 60-80% of patients are diagnosed with #NETCANCER at advanced stage showing the need for symptom awarenesshttp://incalliance.org

Read rest of article.

November 5
2015

NET Cancer Day 2015, Germany. Netzwerk NeT

Veranstaltungen zum NET Cancer Day 2015 des Netzwerk Neuroendokrine Tumoren (NeT) e. V.

For more information: www.netzwerk-net.de

netz

10./11.10.2015:

Hotel NH München Neue Messe

Überregionaler Neuroendokriner Tumortag des Netzwerk Neuroendokrine Tumoren (NeT) e. V., mit zahlreiche Vorträgen und Workshops rund um die Neuroendokrinen Neoplasien

04.11.2015

Uniklinik Mainz

Ergebnisse der neuesten Studien zu NET

Read rest of article.

November 5
2015

The Pheochromocytoma and Paraganglioma 2015 International patient Conference.

pheo nov15

The Pheochromocytoma and Paraganglioma 2015 International patient Conference.

Webcast free of charge, for anyone interested in pheochromocytoma, paraganglioma and MEN.

This patient conference is being held in Syracuse, New Jersey on the 5-7 November (the end of this week) and will be Webcast free of charge, for anyone interested in pheochromocytoma, paraganglioma and MEN.

If interested you can simply register and join us on line, in real time during the event. Details of topics covered and the conference schedule are available on this link  http://www.upstate.edu/cancer/about/conference/schedule.php.

 

(Please note that anyone wishing to register during this last week prior to conference should contact Matt Capogreco the organiser directly, on his email paratroopermatt@gmail.com.

Read rest of article.

October 13
2015

INCA MEETING FEATURES CFCF RESEARCHER: FOCUS ON PRRT

 

Blog post by Ron Hollander.

The International Neuroendocrine Cancer Alliance (INCA) held its annual  Summit and Member meeting in Oxford, England. The assembled representatives from NET groups in 18 nations focused on ways to spread awareness, assist NET groups, and support research for NET patients worldwide. 

INCA-summit-Oxford ron

Read rest of article.

October 4
2015

Good news for NET Cancer

 

Blog post by Bill Claxton.

Good news from Vienna, ECC 2015, the European Cancer Congress,
announced by Philippe Ruszniewski, MD, head of gastroenterology and pancreatology at Beaujon Hospital, in Clichy, France.

bill1

“Treatment with the novel peptide receptor radionuclide therapy (PRRT) Lutathera significantly increased progression-free survival (PFS) over octreotide LAR (Sandostatin) in patients with advanced midgut neuroendocrine tumors (NETs), according to findings from the phase III NETTER-1 trial presented at the 2015 European Cancer Congress.”
Medical abstract is here (www.europeancancercongress) and a press release is here (www.onclive.com).

 

Read rest of article.

September 4
2015

Quality of life – Survey

 

Results from the survey “Quality-of-life”, patients with neuroendocrine tumors (NET)1.

The survey gathered information on the NET patient experience, including diagnosis, disease impact and management, quality of life, and knowledge and awareness levels. Read more here ……..

 

 

 

 

September 4
2015

Quality of life – at ENETS

 

Results from the global survey “Quality-of-life”, patients with neuroendocrine tumors (NET)1. Presented at ENETS, European Neuroendocrine Tumor Society, in Barcelona.

NET Cancer patient experience, including diagnosis, disease impact and management, quality of life, and knowledge and awareness levels.

 

     ENETS-Leyden et al_NET Patient Perspective poster_FINAL  ENETS_Pavel et al_ TimeToDiagnosis poster_FINAL
 Patient Perspective Time to Diagnosis

 

“We hope these survey findings help give people with this type of cancer a voice, and educate the public and healthcare professionals about the personal side of this disease.” said Teodora Kolarova, INCA President.

Read rest of article.

September 4
2015

Not all cancer are pink

 

Why is the zebra associated with NET Cancer?

– Medical students are thought to assume that the simplest explanation is usually the best, i.e., it is usually correct to look for common rather than exotic causes for disease. Doctors learn to expect common conditions, hence the phrase

“If you hear hoofbeats, think horses, not zebras.”

 

Read rest of article.

June 25
2015

Why the Zebra?

Why is the zebra associated with NET Cancer?

In medicine, the term “zebra” is used in reference to a rare disease or condition, like Neuroendocrine (NET) Cancers.

Read rest of article.